324 related articles for article (PubMed ID: 32418884)
1. Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis.
Dolladille C; Font J; Bejan-Angoulvant T; Zaman K; Sassier M; Ezine E; Stefan A; Plane AF; Legallois D; Milliez P; Parienti JJ; Alexandre J
Arch Cardiovasc Dis; 2020; 113(6-7):420-432. PubMed ID: 32418884
[TBL] [Abstract][Full Text] [Related]
2. Ocular Safety Profile of BRAF and MEK Inhibitors: Data from the World Health Organization Pharmacovigilance Database.
Mettler C; Monnet D; Kramkimel N; Tréluyer JM; Mouthon L; Brézin A; Dupin N; Valnet-Rabier MB; Chouchana L; Terrier B
Ophthalmology; 2021 Dec; 128(12):1748-1755. PubMed ID: 34000304
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
Guha A; Jain P; Fradley MG; Lenihan D; Gutierrez JM; Jain C; de Lima M; Barnholtz-Sloan JS; Oliveira GH; Dowlati A; Al-Kindi S
Cancer Med; 2021 Jun; 10(12):3862-3872. PubMed ID: 33982883
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis.
Mincu RI; Mahabadi AA; Michel L; Mrotzek SM; Schadendorf D; Rassaf T; Totzeck M
JAMA Netw Open; 2019 Aug; 2(8):e198890. PubMed ID: 31397860
[TBL] [Abstract][Full Text] [Related]
5. Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system.
Huang S; Guo Z; Wang M; She Y; Ye X; Zhai Q; Liu J; Du Q
Expert Opin Drug Saf; 2023 Feb; 22(2):175-181. PubMed ID: 36896641
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials.
Mai R; Zhou S; Zhong W; Rong S; Cong Z; Li Y; Xie Q; Chen H; Li X; Liu S; Cheng Y; Huang Y; Zhou Y; Zhang G
Oncotarget; 2015 Sep; 6(29):28502-12. PubMed ID: 26143635
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials.
Liu M; Yang X; Liu J; Zhao B; Cai W; Li Y; Hu D
Oncotarget; 2017 May; 8(19):32258-32269. PubMed ID: 28416755
[TBL] [Abstract][Full Text] [Related]
8. Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics.
Patras de Campaigno E; Bondon-Guitton E; Laurent G; Montastruc F; Montastruc JL; Lapeyre-Mestre M; Despas F
Br J Clin Pharmacol; 2017 Jul; 83(7):1544-1555. PubMed ID: 28098949
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors.
Bronte E; Bronte G; Novo G; Rinaldi G; Bronte F; Passiglia F; Russo A
Pharmacol Ther; 2018 Dec; 192():65-73. PubMed ID: 29964124
[TBL] [Abstract][Full Text] [Related]
10. BRAF/MEK inhibitor-associated nephrotoxicity in a real-world setting and human kidney cells.
Sanagawa A; Hotta Y; Mori N; Tomita N; Kataoka T; Tohkin M; Kimura K
Anticancer Drugs; 2021 Nov; 32(10):1076-1083. PubMed ID: 34232935
[TBL] [Abstract][Full Text] [Related]
11. Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis.
Pala L; De Pas T; Pagan E; Minucci S; Catania C; Digiacomo N; Cocorocchio E; Laszlo D; Di Muzio A; Barigazzi C; Stucchi E; De Grandi L; Stucchi S; Viale G; Gelber RD; Bagnardi V; Conforti F
Semin Oncol; 2023; 50(1-2):34-39. PubMed ID: 36967333
[TBL] [Abstract][Full Text] [Related]
12. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
Daud A; Tsai K
Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
[TBL] [Abstract][Full Text] [Related]
13. BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series.
Butt SU; Mejias A; Morelli C; Torga G; Happe M; Patrikidou A; Arkenau HT
Cancer Chemother Pharmacol; 2021 Mar; 87(3):437-441. PubMed ID: 33537843
[TBL] [Abstract][Full Text] [Related]
14. [BRAF inhibitor and MEK inhibitor].
Uhara H
Gan To Kagaku Ryoho; 2015 Apr; 42(4):428-33. PubMed ID: 26020982
[No Abstract] [Full Text] [Related]
15. Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors.
Arangalage D; Degrauwe N; Michielin O; Monney P; Özdemir BC
Cancer Treat Rev; 2021 Nov; 100():102282. PubMed ID: 34438238
[TBL] [Abstract][Full Text] [Related]
16. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects.
Urner-Bloch U; Urner M; Jaberg-Bentele N; Frauchiger AL; Dummer R; Goldinger SM
Eur J Cancer; 2016 Sep; 65():130-8. PubMed ID: 27497344
[TBL] [Abstract][Full Text] [Related]
17. Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study.
Cepaityte D; Siafis S; Egberts T; Leucht S; Kouvelas D; Papazisis G
Schizophr Bull; 2021 Apr; 47(3):672-681. PubMed ID: 33289848
[TBL] [Abstract][Full Text] [Related]
18. The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis.
Chen P; Chen F; Zhou B
Cutan Ocul Toxicol; 2019 Jun; 38(2):105-111. PubMed ID: 30501438
[TBL] [Abstract][Full Text] [Related]
19. SGLT-2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization's adverse drug reactions database.
Ado Moumouni AN; Robin P; Hillaire-Buys D; Faillie JL
Fundam Clin Pharmacol; 2018 Apr; 32(2):216-226. PubMed ID: 29144574
[TBL] [Abstract][Full Text] [Related]
20. A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19.
Diaby V; Almutairi RD; Chen Z; Moussa RK; Berthe A
Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):159-168. PubMed ID: 33186061
[No Abstract] [Full Text] [Related]
[Next] [New Search]